

P1125 CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Topic: 18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical

Loretta Nastoupil¹, Franck Morschhauser², Christian W. Scholz³, Mark Bishton⁴, Sung-Soo Yoon⁵, Pratyush Giri⁶, Michael C. Wei⁷, Andrea Knapp⁸, Chi-Chung Li⁷, Alessia Bottos⁸, Haocheng Li⁹, Enkhtsetseg Purev⁷, Nancy L. Bartlett¹⁰

¹ Emory University, Atlanta, GA, United States; ² University of Lille, CHU Lille, Lille, France; ³ Vivantes Klinikum am Urban, Berlin, Germany; ⁴ Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; ⁵ Seoul National University Hospital, Seoul, Korea, Republic Of; ⁶ Royal Adelaide Hospital, Adelaide, Australia; ⁷ Genentech, Inc., South San Francisco, CA, United States; ⁸ F. Hoffmann-La Roche Ltd, Basel, Switzerland; ⁹ Hoffmann-La Roche Ltd, Mississauga, ON, Canada; ¹⁰ Washington University School of Medicine, St. Louis, United States

Background: Despite significant progress with first-line immunochemotherapy, most patients with follicular lymphoma (FL) will eventually relapse with increasing refractoriness and decreasing duration of response to subsequent therapy lines (Rivas-Delgado et al. 2019). Mosunetuzumab (M) is a CD20xCD3 bispecific antibody that engages and redirects T-cells to eliminate malignant B cells (Sun et al. 2015). In an ongoing, pivotal Phase I/II trial of M monotherapy, patients with relapsed/refractory (R/R) FL who have received ≥ 2 prior treatment lines achieve deep and durable responses (NCT02500407; Budde et al. ASH 2021). Preliminary data from a Phase Ib study have suggested favorable safety and promising activity of M in combination with lenalidomide (Len), a potent immunomodulatory agent that has shown additive/synergistic activity with an anti-CD20 antibody in R/R indolent lymphoma (Leonard et al. 2019), in patients with R/R FL who have received ≥ 1 prior therapy (NCT4246086; Morschhauser et al. ASH 2021). The chemotherapy-free M-Len combination may represent a promising outpatient therapy option for future management of patients with R/R FL. The randomized, multicenter Phase III study has been initiated.

Aims: CELESTIMO (NCT04712097) is a randomized, multicenter, open-label Phase III study evaluating the efficacy and safety of M-Len versus rituximab plus Len (R-Len) in patients with previously treated R/R FL.

Methods: Patients must have histologically documented CD20+ FL (Grades 1–3a) requiring systemic therapy and have received ≥ 1 prior line of systemic therapy. Patients are randomized (1:1) to receive M-Len (M intravenously [IV] on Days [D] 1, 8 and 15 of Cycle [C] 1 [21-day cycle] and D1 of C2–12 [28-day cycles], plus Len orally [PO] on D1–21 of C2–12) or R-Len (R IV on D1, 8, 15 and 22 of C1 then on D1 of C3, 5, 7, 9, and 11, plus Len PO on D1–21 of C1–12 [all 28-day cycles]), and stratified by disease progression within 24 months of initial treatment (yes/no), number of prior lines of therapy (1 versus ≥ 2), and refractoriness to anti-CD20 therapy (refractory/non-refractory). All patients must provide informed consent.

Results: The primary endpoint is progression-free survival (PFS) assessed by independent review committee; secondary endpoints include investigator-assessed PFS, complete and objective response, overall survival, and safety. Biomarkers predictive of response to M-Len and R-Len will also be investigated as exploratory endpoints.

Summary/Conclusion: The study started recruitment in 2021 and plans to enroll ~400 patients from approximately 16 countries and 150 sites globally. Further study details will be presented.

© American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2022 ASCO Annual Meeting. All rights reserved.

Copyright Information: (Online) ISSN: 2572-9241

© 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2022;6:(S3):pages. The individual abstract DOIs can be found at <https://journals.lww.com/hemasphere/pages/default.aspx>.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.